Suppr超能文献

重组可溶性尿激酶受体作为尿激酶型纤溶酶原激活剂(uPA)的清除剂。对人卵巢癌细胞增殖和侵袭的抑制作用。

Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells.

作者信息

Wilhelm O, Weidle U, Höhl S, Rettenberger P, Schmitt M, Graeff H

机构信息

Frauenklinik der TU München, Klinikum rechts der Isar, Germany.

出版信息

FEBS Lett. 1994 Jan 10;337(2):131-4. doi: 10.1016/0014-5793(94)80259-9.

Abstract

A recombinant soluble human urokinase receptor comprising amino acids 1-277 was cloned and transfected into CHO cells. The mutant protein (rec-uPAR277), purified from the CHO cell supernatant by affinity chromatography on immobilized urokinase (uPA), in a four-fold excess, completely abolished the binding of FITC-labeled pro-uPA to the human ovarian cancer cell line, OV-MZ-6. This invasive and tumorigenic cancer cell line expresses uPA, its inhibitor PAI-1, and the high-affinity receptor for uPA, uPAR. Rec-uPAR277 significantly reduced the proliferation of OV-MZ-6 cells in a concentration-dependent manner without altering the viability of the cells. Invasion of OV-MZ-6 cells tested in an in vitro Matrigel invasion assay was inhibited by rec-uPAR277 up to 75%. In conclusion, these results demonstrate that rec-uPAR277 can function as a scavenger for uPA in vitro by inhibiting proliferation and invasion of human cancer cells.

摘要

一种包含1 - 277个氨基酸的重组可溶性人尿激酶受体被克隆并转染到CHO细胞中。通过固定化尿激酶(uPA)亲和层析从CHO细胞上清液中纯化得到的突变蛋白(rec-uPAR277),以四倍过量完全消除了异硫氰酸荧光素(FITC)标记的pro-uPA与人卵巢癌细胞系OV-MZ-6的结合。这种具有侵袭性和致瘤性的癌细胞系表达uPA、其抑制剂PAI-1以及uPA的高亲和力受体uPAR。Rec-uPAR277以浓度依赖的方式显著降低了OV-MZ-6细胞的增殖,而不改变细胞的活力。在体外基质胶侵袭试验中测试发现,rec-uPAR277对OV-MZ-6细胞侵袭的抑制率高达75%。总之,这些结果表明rec-uPAR277在体外可通过抑制人癌细胞的增殖和侵袭而作为uPA的清除剂发挥作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验